Adjuvant‐mediated enhancement of the immune response to HIV vaccines

Ratnapriya, Sneha; Perez-Greene, Eva; Schifanella, Luca; Herschhorn, Alon

doi:10.1111/febs.15814

Cited by 15 publications

(15 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The induction of certain cytokine repertoires by adjuvants has been shown to inhibit virus replication, namely hepatitis B [ 163 ] and enhance the immunity of antiviral vaccines including HIV [ 164 ] and influenza [ 165 ], with the latter demonstrating increased induction of T-helper type 1 (Th1)-biased cytokines. Therefore, the selection of an appropriate adjuvant is influenced by the type of CD4+ T-cell response required for protection but may represent an opportunity for prophylactic immunomodulation to support the use of combination immunotherapy.…”

Section: Strategies To Address the Deviant Responsementioning

confidence: 99%

Understanding Immune Responses to Viruses—Do Underlying Th1/Th2 Cell Biases Predict Outcome?

Howard

Kwan

Winder

et al. 2022

Viruses

View full text Add to dashboard Cite

Emerging and re-emerging viral diseases have increased in number and geographical extent during the last decades. Examples include the current COVID-19 pandemic and the recent epidemics of the Chikungunya, Ebola, and Zika viruses. Immune responses to viruses have been well-characterised within the innate and adaptive immunity pathways with the outcome following viral infection predominantly attributed to properties of the virus and circumstances of the infection. Perhaps the belief that the immune system is often considered as a reactive component of host defence, springing into action when a threat is detected, has contributed to a poorer understanding of the inherent differences in an individual’s immune system in the absence of any pathology. In this review, we focus on how these host factors (age, ethnicity, underlying pathologies) may skew the T helper cell response, thereby influencing the outcome following viral infection but also whether we can use these inherent biases to predict patients at risk of a deviant response and apply strategies to avoid or overcome them.

show abstract

Section: Strategies To Address the Deviant Responsementioning

confidence: 99%

Understanding Immune Responses to Viruses—Do Underlying Th1/Th2 Cell Biases Predict Outcome?

Howard

Kwan

Winder

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…The latter observation is consistent with results with other viral vectors expressing Env proteins 1 , 39 . In contrast, Env protein vaccination when in combination with a strong adjuvant, is associated with high Ab responses, that are, however, not very durable 16 – 18 , 40 . As shown in Fig.…”

Section: Resultsmentioning

confidence: 95%

Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers

et al. 2022

View full text Add to dashboard Cite

Integrase Defective Lentiviral Vectors (IDLVs) represent an attractive vaccine platform for delivering HIV-1 antigens, given their ability to induce specific and persistent immune responses in both mice and non-human primates (NHPs). Recent advances in HIV-1 immunogen design demonstrated that native-like HIV-1 Envelope (Env) trimers that mimic the structure of virion-associated Env induce neutralization breadth in rabbits and macaques. Here, we describe the development of an IDLV-based HIV-1 vaccine expressing either soluble ConSOSL.UFO.664 or membrane-tethered ConSOSL.UFO.750 native-like Env immunogens with enhanced bNAb epitopes exposure. We show that IDLV can be pseudotyped with properly folded membrane-tethered native-like UFO.750 trimers. After a single IDLV injection in BALB/c mice, IDLV-UFO.750 induced a faster humoral kinetic as well as higher levels of anti-Env IgG compared to IDLV-UFO.664. IDLV-UFO.750 vaccinated cynomolgus macaques developed unusually long-lasting anti-Env IgG antibodies, as underlined by their remarkable half-life both after priming and boost with IDLV. After boosting with recombinant ConM SOSIP.v7 protein, two animals developed neutralization activity against the autologous tier 1B ConS virus mediated by V1/V2 and V3 glycan sites responses. By combining the possibility to display stabilized trimeric Env on the vector particles with the ability to induce sustained humoral responses, IDLVs represent an appropriate strategy for delivering rationally designed antigens to progress towards an effective HIV-1 vaccine.

show abstract

“…As depicted in Figures 2B,C , adjuvants enhance the immune response to the two RBD-based subunit vaccines, especially of the group immunized via intraperitoneal injection. Intraperitoneal route could elicit a higher immunity and dissemination compared to the other ways such as oral gavage and aerosol ( 36 , 37 ). Intriguingly, to the contrary of robust antibodies against RBD, groups vaccinated with RBD+adju IP and RBD+adju IN did not elicit a high neutralization titer against the SARS-CoV-2 spike protein to inhibit viral entry through the ACE2 receptor of HEK293 ( Figures 2D,E ), indicating that binding antibodies are not directly proportional to the neutralizing potency ( 38 ).…”

Section: Discussionmentioning

confidence: 99%

Delivery of spike-RBD by bacterial type three secretion system for SARS-CoV-2 vaccine development

Zhou

Qu²,

Sun³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

COVID-19 pandemic continues to spread throughout the world with an urgent demand for a safe and protective vaccine to effectuate herd protection and control the spread of SARS-CoV-2. Here, we report the development of a bacterial vector COVID-19 vaccine (aPA-RBD) that carries the gene for the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Live-attenuated strains of Pseudomonas aeruginosa (aPA) were constructed which express the recombinant RBD and effectively deliver RBD protein into various antigen presenting cells through bacterial type 3 secretion system (T3SS) in vitro. In mice, two-dose of intranasal aPA-RBD vaccinations elicited the development of RBD-specific serum IgG and IgM. Importantly, the sera from the immunized mice were able to neutralize host cell infections by SARS-CoV-2 pseudovirus as well as the authentic virus variants potently. T-cell responses of immunized mice were assessed by enzyme-linked immunospot (ELISPOT) and intracellular cytokine staining (ICS) assays. aPA-RBD vaccinations can elicit RBD-specific CD4+and CD8+T cell responses. T3SS-based RBD intracellular delivery heightens the efficiency of antigen presentation and enables the aPA-RBD vaccine to elicit CD8+T cell response. Thus, aPA vector has the potential as an inexpensive, readily manufactured, and respiratory tract vaccination route vaccine platform for other pathogens

show abstract

Adjuvant‐mediated enhancement of the immune response to HIV vaccines

Cited by 15 publications

References 142 publications

Understanding Immune Responses to Viruses—Do Underlying Th1/Th2 Cell Biases Predict Outcome?

Understanding Immune Responses to Viruses—Do Underlying Th1/Th2 Cell Biases Predict Outcome?

Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers

Delivery of spike-RBD by bacterial type three secretion system for SARS-CoV-2 vaccine development

Contact Info

Product

Resources

About